Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.20) by 84.5 percent. This is a 99.26 percent increase over losses of $(4.20) per share from the same period last year. The company reported quarterly sales of $51.342 million which missed the analyst consensus estimate of $72.000 million by 28.69 percent. This is a 1.53K percent increase over sales of $3.156 million the same period last year.